The 20th anniversary of interleukin-2 therapy: Bimodal role explaining longstanding random induction of complete clinical responses

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 215-221

  Coventry, Brendon J ^a   Ashdown, Martin L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bimodal role; Cancer therapy; Complete responses; Cytokines; Immune modulation; Immune response; Immunotherapy; Interleukin 2; Regulatory T cells; Translational research

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ADVANCED CANCER; CHRONIC DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; KIDNEY CARCINOMA; LYMPHOCYTE SUBPOPULATION; MELANOMA; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 84930479671     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S33979     Document Type: Review

References (36)

1. Smith KA. The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs. Med Immunol. 2006;5:3-8.
2. Grivas PD, Redman BG. Immunotherapy of kidney cancer. Curr Clin Pharmacol. 2011;6:151-163.
3. Murphy WJ, et al. Community corner-a delicate balance: tweaking IL-2 immunotherapy. Nat Med. 2012;18:208-209.
4. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055-2066.
5. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365:2067-2077.
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17: 2105-2116.
7. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for highdose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6 Suppl 1:S55-S57.
8. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008; 113:293-301.
9. Sojka DK, Hughson A, Sukiennicki TL, Fowell DJ. Early kinetic window of target T cell susceptibility to CD25wwregulatory T cell activity. J Immunol. 2005;175:7274-7280.
10. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005;202:1375-1386.
11. Abbas AK, Lichtman AH. Cellular and Molecular Immunology. 5th ed. Philadelphia, PA: Elsevier-Saunders; 2005.
12. McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. CD41 CD25CCregulatory T cells control CD8rrT-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A. 2011;108: 7529-7534.
13. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12: 180-190.
14. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD41 CD25(hi) Foxp3CCregulatory T cells in cancer patients. Blood. 2006;107: 2409-2414.
15. Coventry BJ, Ashdown ML, Markovic SN. Immune therapies for cancer: bimodality-the blind spot to clinical efficacy-lost in translation. J Immunother. 2011;34:717.
16. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-2047.
17. Quan WD Jr, Quan FM, Perez M, Johnson E. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma. Cancer Biother Radiopharm. June 25, 2012. [Epub ahead of print.]
18. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169-1188.
19. Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K. Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563. Cancer Immunol Immunother. 1986;23:25-30.
20. Shrikant P, Mescher MF. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J Immunol. 2002;169:1753-1759.
21. Jackaman C, Bundell CS, Kinnear BF, et al. IL-2 intratumoral immunotherapy enhances CD8iiT cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003;171:5051-5063.
22. Feinerman O, Jentsch G, Tkach KE, et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol. 2010;6:437.
23. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645-2652.
24. Panelli MC, Nagorsen D, Wang E, et al. Mechanism of immune response during immunotherapy. Yonsei Med J. 2004;45 Suppl:15-17.
25. Rangel-Corona R, Corona-Ortega T, Soto-Cruz I, et al. Evidence that cervical cancer cells secrete IL-2, which becomes an autocrine growth factor. Cytokine. 2010;50:273-277.
26. Plaisance S, Rubinstein E, Alileche A, et al. Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer. 1993;55: 164-170.
27. Alileche A, Plaisance S, Han DS, et al. Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene. 1993;8:1791-1796.
28. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM. Lack of interleukin-2 (IL-2) cytokine expression despite IL-2 mRNA transcription in tumor infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J Immunol. 1996;156:3486-3492.
29. Barbour AH, Coventry BJ. Dendritic cell density and activation status of tumour-infiltrating lymphocytes in metastatic human melanoma: possible implications for sentinel node metastases. Melanoma Res. 2003;13:263-269.
30. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
31. Ashdown ML, Coventry BJ. A matter of time. Australasian Science. 2010:18-20.
32. Coventry BJ, Hersey P, Halligan A-M, Michele A. Immuno-chemotherapy using repeated vaccine treatment can produce successful clinical responses in advanced metastatic melanoma. J Cancer Ther. 2010;1: 205-213.
33. Holtan SG, Dronca RS, Nevala WK, et al. The dynamic human immune response to cancer: it might just be rocket science. Immunotherapy. 2011;3:1021-1024.
34. Leontovich AA, Dronca RS, Suman VJ, et al. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012;4:958-975.
35. Coventry BJ, Ashdown ML. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res. 2012;4:137-149.
36. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A. 2011;107:1524-1528.